Prostate cancer (metastatic, hormone relapsed, not treated with chemotherapy) - abiraterone acetate (with prednisolone) [ID503]: evaluation report

Please be advised that the format of evaluation reports shared on the NICE website has recently changed, for ease of user navigation between individual documents contained in the report.

It is a requirement of the new (PDF portfolio) format that Adobe Reader is used to view the document. Please follow the link at the bottom of this page to download Adobe Reader if required.

If you have any feedback on the new format please contact the Project Manager for this appraisal.

Evaluation report:

01 - Pre-Meeting Briefing prepared by NICE

02 - Submission from the technology manufacturer - Janssen

03 - NICE request to the manufacturer for clarification on their submission

04 - Manufacturer clarification response

05 - Consultee submission -  Prostate Cancer UK

06 - Consultee submission - Tackle Prostate Cance

07 - Consultee submission - BAUS

08 - Consultee submission - British Uro-oncology Group

09 - Consultee submission - NCRI-RCP-RCR-ACP-JCCO

10 - Expert personal perspective from Dr John Graham

11 - Expert personal perspective from Dr Simon Hughes

12 - Expert personal perspective from David Smith

13 - Expert personal perspective from Stuart Watson

14 - Evidence Review Group report prepared by Kleijnen Systematic Reviews

15 - Erratum to Evidence Review Group report prepared by Kleijnen Systematic Reviews

16 - Manufacturer factual accuracy check of Evidence Review Group report

This page was last updated: 09 May 2014